Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Assetmark Inc.

Assetmark Inc. raised its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 16.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,212 shares of the company’s stock after acquiring an additional 748 shares during the quarter. Assetmark Inc.’s holdings in Castle Biosciences were worth $149,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CSTL. US Bancorp DE lifted its holdings in Castle Biosciences by 1,889.2% in the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after acquiring an additional 4,383 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Castle Biosciences by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock valued at $152,000 after acquiring an additional 2,093 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Castle Biosciences by 10.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock valued at $215,000 after acquiring an additional 952 shares during the period. XTX Topco Ltd acquired a new position in Castle Biosciences in the second quarter valued at approximately $218,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Castle Biosciences by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock valued at $220,000 after acquiring an additional 675 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on CSTL. BTIG Research upped their target price on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Canaccord Genuity Group upped their target price on Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, October 29th. Stephens reaffirmed an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. Lake Street Capital upped their target price on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, Robert W. Baird upped their target price on Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $37.88.

Castle Biosciences Stock Down 8.9 %

Shares of NASDAQ:CSTL opened at $28.10 on Monday. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $31.14 and a two-hundred day moving average of $26.32. The stock has a market cap of $787.08 million, a P/E ratio of 140.51 and a beta of 0.99. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. The company had revenue of $85.78 million during the quarter, compared to analysts’ expectations of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same period in the prior year, the business earned ($0.26) EPS. On average, research analysts expect that Castle Biosciences, Inc. will post -0.08 earnings per share for the current year.

Insider Buying and Selling at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $29.44, for a total transaction of $231,604.48. Following the completion of the transaction, the director now directly owns 5,700 shares in the company, valued at approximately $167,808. This represents a 57.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Derek J. Maetzold sold 986 shares of the stock in a transaction on Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the transaction, the insider now owns 94,622 shares of the company’s stock, valued at approximately $2,718,490.06. This represents a 1.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,290 shares of company stock worth $545,468 in the last three months. 7.20% of the stock is owned by corporate insiders.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.